Enovix (NASDAQ:ENVX) Price Target Lowered to $7.50 at TD Cowen

Enovix (NASDAQ:ENVX) had its target price reduced by research analysts at TD Cowen from $15.00 to $7.50 in a research note issued on Thursday. The brokerage presently has a “hold” rating on the stock. TD Cowen’s target price indicates a potential upside of 21.95% from the stock’s current price.

ENVX has been the topic of a number of other reports. JPMorgan Chase & Co. reduced their price objective on shares of Enovix from $12.00 to $10.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enovix in a report on Monday, December 29th. Canaccord Genuity Group decreased their price objective on shares of Enovix from $22.00 to $21.00 and set a “buy” rating on the stock in a research note on Thursday, November 6th. Northland Securities set a $16.00 price objective on shares of Enovix in a research report on Monday, November 17th. Finally, Oppenheimer set a $24.00 target price on Enovix in a report on Thursday, November 6th. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $16.75.

Enovix Price Performance

Shares of Enovix stock opened at $6.15 on Thursday. The company has a quick ratio of 9.47, a current ratio of 9.72 and a debt-to-equity ratio of 1.74. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -7.59 and a beta of 2.13. Enovix has a twelve month low of $5.27 and a twelve month high of $16.49. The company has a 50-day simple moving average of $7.19 and a two-hundred day simple moving average of $8.96.

Hedge Funds Weigh In On Enovix

Hedge funds have recently made changes to their positions in the stock. Caitlin John LLC bought a new position in shares of Enovix during the 3rd quarter worth approximately $27,000. Parallel Advisors LLC lifted its position in shares of Enovix by 51.9% during the 3rd quarter. Parallel Advisors LLC now owns 3,926 shares of the company’s stock valued at $39,000 after acquiring an additional 1,342 shares during the period. CWM LLC boosted its stake in Enovix by 95.4% during the fourth quarter. CWM LLC now owns 6,081 shares of the company’s stock worth $44,000 after acquiring an additional 2,969 shares in the last quarter. Stone House Investment Management LLC grew its holdings in Enovix by 56.4% in the third quarter. Stone House Investment Management LLC now owns 7,922 shares of the company’s stock worth $79,000 after purchasing an additional 2,857 shares during the period. Finally, Wilmington Savings Fund Society FSB bought a new stake in Enovix in the third quarter valued at $80,000. 50.92% of the stock is currently owned by institutional investors.

Key Headlines Impacting Enovix

Here are the key news stories impacting Enovix this week:

• Positive Sentiment: Q4 revenue and EPS beat consensus — Enovix reported revenue of roughly $11.3M (≈+16% YoY) and an EPS loss smaller than expected (-$0.14 vs. consensus -$0.17), which shows improving top-line traction and a narrower-than-feared loss. Enovix Corporation (ENVX) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Gross-profit and operating improvement — Gross profit rose sharply year-over-year and operating loss narrowed (~27% improvement), suggesting margins are beginning to recover as volumes grow. Enovix Corporation (ENVX) Stock Falls on Q4 2025 Earnings
• Neutral Sentiment: Management emphasizes manufacturing ramp and market expansion — The earnings call highlighted strategic market expansion and a continued manufacturing scale-up that could boost future revenue but carries execution risk and timing uncertainty. Enovix Corp (ENVX) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: EPS guidance slightly better than Street — Q1 EPS guidance of -$0.18 to -$0.14 compares favorably to consensus (-$0.19), which limits downside on near-term profitability expectations. Enovix Corporation (ENVX) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
• Negative Sentiment: Revenue guidance misses Street — Q1 revenue guide of $6.5M–$7.5M is below consensus (~$8.8M), which signals near-term growth softness and was a primary driver of the share decline. Enovix Q4 Release / Guidance (Press Release / Slides)
• Negative Sentiment: Liquidity and balance-sheet concerns — Cash fell to ~ $106M (year-over-year decline) and reported total liabilities rose materially, raising financing and cash‑burn concerns while the company scales manufacturing. Enovix Corporation (ENVX) Stock Falls on Q4 2025 Earnings (Quiver)
• Negative Sentiment: Insider sales and mixed institutional flows — Recent insider selling and large portfolio moves by institutions add pressure and may signal shorter-term skepticism among some holders. Enovix Corporation (ENVX) Stock Falls on Q4 2025 Earnings (Quiver)

Enovix Company Profile

Enovix Corporation (NASDAQ: ENVX) develops and manufactures advanced lithium-ion battery cells with a patented three-dimensional silicon-anode architecture. The company’s core focus is on delivering high energy density, improved safety, and longer cycle life compared to conventional graphite-based cells. Enovix’s technology targets a range of applications, including consumer electronics, wearable devices, electric vehicles and stationary energy storage systems.

Founded in 2011 and headquartered in Fremont, California, Enovix has built pilot production capability and is scaling up manufacturing capacity to meet growing demand.